Influence of the ABCB1 polymorphisms on the response to Taxane-containing chemotherapy: a systematic review and meta-analysis

Jiang, Qi; Xu, Miaomiao; Liu, Yina; Chen, Yudi; Feng, Jiarong; Wang, Xuelin; Liang, Shuang; Li, Dan; Yang, Xiaoqin

doi:10.1007/s00280-017-3496-1

Cited by 4 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is consistent with the results of two previous multicenter studies conducted in the United States and Japan. A meta-analysis reported by Jiang et al, (2018) revealed that the rs1045642 and rs1128503 polymorphisms were not related to the response to chemotherapy. Although heterogeneities were found in the overall analyses of PFS and OS in the C3435T homozygote and dominant models, subgroup analysis identified geographical area, tumor type, and chemotherapy regimen as the three main sources of heterogeneity between studies.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Two Polymorphisms, rs1045642 and rs1128503, in ABCB1 Following Taxane-based Chemotherapy: A Meta-Analysis

Chen

Lin

Yang

et al. 2021

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Two Polymorphisms, rs1045642 and rs1128503, in ABCB1 Following Taxane-based Chemotherapy: A Meta-Analysis

Chen

Lin

Yang

et al. 2021

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…This is consistent with the results of two previous multicenter studies in the United States and Japan. A metaanalysis reported by Jiang revealed that the rs1045642 and rs1128503 polymorphisms were not related to the response to chemotherapy [37]. Although heterogeneities were found in the overall analyses of PFS and OS in the C3435T homozygote and dominant models, we conducted subgroup analysis and identified the geographical area, tumor type, and chemotherapy regimen as the three main sources of heterogeneity between studies.…”

Section: Discussionmentioning

confidence: 98%

Predictive value of two polymorphisms in ABCB1, rs1045642 and rs1128503, in prognosis following taxane-containing chemotherapy: A meta-analysis

Chen

Lin

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Although taxane-containing chemotherapy is widely used to treat solid tumors, genetic polymorphisms can influence the chemotherapeutic response. This meta-analysis was conducted to determine the correlation between two polymorphisms in ABCB1 , rs1045642 and rs1128503, and survival of patients administered taxane-containing chemotherapy. Methods: PubMed, Web of Science, Embase, Wanfang database, VIP database, and China National Knowledge Infrastructure database were used to obtain articles published up to August 2019 describing the association between the ABCB1 rs1045642 and rs1128503 polymorphisms and survival. A meta-analysis was conducted using R 3.6.1 software to determine the pooled hazard ratio (HR) and 95% confidence intervals (95% CI). Furthermore, publication bias was assessed, and sensitivity analysis was performed to validate the analysis. Results: Fifteen studies involving 3320 patients were included in the meta-analysis. The summary results showed that the effect of the C1236T polymorphism on progression-free survival remained significant in the heterozygote model (HR 0.81; 95% CI: 0.67–0.98) and homozygote model (HR 0.71; 95% CI: 0.58–0.88). Compared to the C1236 TT phenotype, the CC genotype was associated with a poor overall survival (HR 0.72; 95% CI: 0.53–0.97). Finally, subgroup analysis suggested that different areas, tumor types, and treatment regimens influence patient survival. Conclusions: Patients who are ABCB1 rs1045642 and rs1128503 T gene carriers show a survival benefit with taxane-containing chemotherapy.

show abstract

“…A meta-analysis by Chen et al [ 12 ], including prospective studies of taxane-treated breast, lung, ovarian, gastric, and head/neck cancer patients, reported better survival in ABCB1 rs1128503 variant carriers, consistent with our findings [ 12 ]. Another meta-analysis including case–control studies did not detect such associations in breast cancer patients, but had limited precision [ 42 ]. In the study by Chen et al [ 12 ], no overall associations were found for ABCB1 rs1045642, but poor overall survival was found in European populations homozygote for the variant allele, consistent with the increased mortality observed in our study.…”

Section: Discussionmentioning

confidence: 99%

Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark

Hjorth

Damkier

Stage

et al. 2022

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose Taxane-based chemotherapy is the primary treatment for premenopausal breast cancer. Although being inconsistent, research suggests that variant alleles alter pharmacokinetics through reduced function of OATP transporters (limiting hepatic uptake), CYP-450 enzymes (hampering drug metabolism), and ABC transporters (decreasing clearance). Reduced function of DNA repair enzymes may hamper effectiveness through dose-limiting toxicities. We investigated whether single-nucleotide polymorphisms (SNPs) were associated with breast cancer recurrence or mortality in premenopausal women diagnosed with breast cancer. Methods We conducted a population-based cohort study of premenopausal women diagnosed with non-distant metastatic breast cancer in Denmark during 2007‒2011, when guidelines recommended adjuvant combination chemotherapy (taxanes, anthracyclines, and cyclophosphamide). Using archived formalin-fixed paraffin-embedded primary tumor tissue, we genotyped 26 SNPs using TaqMan assays. Danish health registries provided data on breast cancer recurrence (through September 25, 2017) and death (through December 31, 2019). We fit Cox regression models to calculate crude hazard ratios (HRs) and 95% confidence intervals (CIs) for recurrence and mortality across genotypes. Results Among 2,262 women, 249 experienced recurrence (cumulative incidence: 13%) and 259 died (cumulative incidence: 16%) during follow-up (median 7.0 and 10.1 years, respectively). Mortality was increased in variant carriers of GSTP1 rs1138272 (HR: 1.30, 95% CI 0.95–1.78) and CYP3A rs10273424 (HR: 1.33, 95% CI 0.98–1.81). SLCO1B1 rs2306283 (encoding OATP1B1) variant carriers had decreased recurrence (HR: 0.82, 95% CI 0.64–1.07) and mortality (HR: 0.77, 95% CI 0.60–0.98). Conclusion Docetaxel effectiveness was influenced by SNPs in GSTP1, CYP3A, and SLCO1B1 in premenopausal women with non-distant metastatic breast cancer, likely related to altered docetaxel pharmacokinetics. These SNPs may help determine individual benefit from taxane-based chemotherapy.

show abstract

Influence of the ABCB1 polymorphisms on the response to Taxane-containing chemotherapy: a systematic review and meta-analysis

Abstract: This study highlights the unsuitability of relying on the ABCB1 rs1045642 and rs1128503 polymorphisms as therapeutic response biomarkers of Taxane-containing chemotherapy. Further polycentric studies in larger and multiracial populations are needed to validate the conclusions.

Cited by 4 publications

References 26 publications

Prognostic Value of Two Polymorphisms, rs1045642 and rs1128503, in ABCB1 Following Taxane-based Chemotherapy: A Meta-Analysis

Prognostic Value of Two Polymorphisms, rs1045642 and rs1128503, in ABCB1 Following Taxane-based Chemotherapy: A Meta-Analysis

Predictive value of two polymorphisms in ABCB1, rs1045642 and rs1128503, in prognosis following taxane-containing chemotherapy: A meta-analysis

Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark

Contact Info

Product

Resources

About